Cargando…

Capmatinib successfully overcomes tepotinib‐induced intolerable peripheral edema

In May 2020 and February 2021, capmatinib and tepotinib, respectively were approved by the Food and Drug Administration (FDA) for the treatment of metastatic non‐small cell lung carcinoma harboring mesenchymal‐epithelial transition (MET) exon 14 skipping alterations. Herein, we present a case of int...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kunimasa, Kei, Kawamura, Takahisa, Tamiya, Motohiro, Inoue, Takako, Kuhara, Hanako, Nishino, Kazumi, Kumagai, Toru
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons Australia, Ltd 2021
Materias:	Case Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8671889/ https://www.ncbi.nlm.nih.gov/pubmed/34695875 http://dx.doi.org/10.1111/1759-7714.14205

Ejemplares similares

Favorable response to pembrolizumab after durvalumab failure in a stage III sarcomatoid carcinoma of the lung: a case report
por: Nishino, Kazumi, et al.
Publicado: (2020)

Manual route modification using an oblique method following automatic virtual bronchoscopic navigation
por: Inoue, Takako, et al.
Publicado: (2022)

Cytokine Release Syndrome and Immune-Related Pneumonitis Associated With Tumor Progression in a Pulmonary Pleomorphic Carcinoma Treated With Nivolumab Plus Ipilimumab Treatment: A Case Report
por: Kunimasa, Kei, et al.
Publicado: (2021)

Conversion Surgery for Advanced Thoracic SMARCA4-Deficient Undifferentiated Tumor With Atezolizumab in Combination With Bevacizumab, Paclitaxel, and Carboplatin Treatment: A Case Report
por: Kunimasa, Kei, et al.
Publicado: (2021)

Rapid Response to Sotorasib of a Patient With KRAS G12C-Mutated Lung Cancer With Cancer-Associated Disseminated Intravascular Coagulation: A Case Report
por: Kunimasa, Kei, et al.
Publicado: (2022)

Infectious pericarditis caused by Gemella sanguinis induced by Endobronchial Ultrasound-guided Transbronchial Needle Aspiration (EBUS-TBNA): A case report
por: Inoue, Takako, et al.
Publicado: (2020)

Comparison of sampling methods for next generation sequencing for patients with lung cancer
por: Kunimasa, Kei, et al.
Publicado: (2022)

Switching from first or second generation EGFR-TKI to osimertinib in EGFR mutation-positive NSCLC
por: Imamura, Fumio, et al.
Publicado: (2020)

Immunochemotherapy Disrupts Peripherally Located Lung Squamous Cell Carcinoma Resulting in Pleuritis: A Report of Two Cases, Case Report
por: Kunimasa, Kei, et al.
Publicado: (2022)

Successful weaning of a patient with severe COVID-19 pneumonia under prolonged midazolam sedation using morphine
por: Kunimasa, Kei, et al.
Publicado: (2022)

Pembrolizumab-induced acute thrombosis: A case report
por: Kunimasa, Kei, et al.
Publicado: (2018)

Rapid and reliable collection of tumor tissue for successful gene panel in a patient with advanced stage lung cancer: A case report
por: Kunimasa, Kei, et al.
Publicado: (2022)

Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation
por: Fujino, Toshio, et al.
Publicado: (2022)

Afatinib-induced severe esophagitis in a lung cancer patient with an activated epidermal growth factor receptor mutation: A case report
por: Inoue, Takako, et al.
Publicado: (2017)

Delayed pseudoprogression of lung adenocarcinoma accompanied with interstitial lung disease during chemotherapy after nivolumab treatment
por: Kumagai, Toru, et al.
Publicado: (2017)

The impact of EGFR mutation status and single brain metastasis on the survival of non-small-cell lung cancer patients with brain metastases
por: Fujita, Yuya, et al.
Publicado: (2020)

Spotlight on Tepotinib and Capmatinib for Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutation
por: Brazel, Danielle, et al.
Publicado: (2022)

Cardiac Adverse Events in EGFR-Mutated Non-Small Cell Lung Cancer Treated With Osimertinib
por: Kunimasa, Kei, et al.
Publicado: (2020)

Utility of needle biopsy in centrally located lung cancer for genome analysis: a retrospective cohort study
por: Kunimasa, Kei, et al.
Publicado: (2023)

Metastatic site as a predictor of nivolumab efficacy in patients with advanced non-small cell lung cancer: A retrospective multicenter trial
por: Tamiya, Motohiro, et al.
Publicado: (2018)

HER3 expression is enhanced during progression of lung adenocarcinoma without EGFR mutation from stage 0 to IA1
por: Kumagai, Toru, et al.
Publicado: (2018)

Clinical application of comprehensive genomic profiling panel to thoracic malignancies: A single‐center retrospective study
por: Kunimasa, Kei, et al.
Publicado: (2022)

Successful Tepotinib Challenge After Capmatinib-Induced Interstitial Lung Disease in a Patient With Lung Adenocarcinoma Harboring MET Exon 14 Skipping Mutation: Case Report
por: Hashiguchi, Mizuha Haraguchi, et al.
Publicado: (2021)

Cost-Effectiveness of Tepotinib Versus Capmatinib for the Treatment of Adult Patients With Metastatic Non–Small Cell Lung Cancer Harboring Mesenchymal–Epithelial Transition Exon 14 Skipping
por: Yang, Mo, et al.
Publicado: (2023)

A long-term survivor of non-small-cell lung cancer harboring concomitant EGFR mutation and ALK translocation
por: Imamura, Fumio, et al.
Publicado: (2016)

A case of successful desensitization treatment with tepotinib after tepotinib-induced rash
por: Tamura, Tomoki, et al.
Publicado: (2023)

Safety of Tepotinib Challenge after Capmatinib-Induced Pneumonitis in a Patient with Non-Small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation: A Case Report
por: Tseng, Liang-Wei, et al.
Publicado: (2022)

The ratio of T790M to EGFR-activating mutation predicts response of osimertinib in 1st or 2nd generation EGFR-TKI-refractory NSCLC
por: Tamiya, Motohiro, et al.
Publicado: (2021)

Pleural sarcoidosis diagnosed on the basis of an increased CD4/CD8 lymphocyte ratio in pleural effusion fluid: a case report
por: Kumagai, Toru, et al.
Publicado: (2015)

TP53 Loss of Heterozygosity Induces De Novo SCLC Formation in EGFR-Mutated Lung Adenocarcinoma: A Case Report
por: Kunimasa, Kei, et al.
Publicado: (2022)

Fragment size and dynamics of EGFR-mutated tumor-derived DNA provide prognostic information regarding EGFR-TKI efficacy in patients with EGFR-mutated NSCLC
por: Kunimasa, Kei, et al.
Publicado: (2022)

Pseudo-acute kidney injury secondary to tepotinib
por: Wijtvliet, Veerle, et al.
Publicado: (2022)

Arsenical Intolerance Overcome by Desensitization
por: Chaudhuri, R. N.
Publicado: (1936)

Pneumothorax triggered by the combination of gefitinib and amrubicin and treated with endobronchial silicone spigots
por: Imamura, Fumio, et al.
Publicado: (2015)

Transient appearance of circulating tumor DNA associated with de novo treatment
por: Kato, Kikuya, et al.
Publicado: (2016)

Early responses of EGFR circulating tumor DNA to EGFR tyrosine kinase inhibitors in lung cancer treatment
por: Imamura, Fumio, et al.
Publicado: (2016)

Response to Capmatinib in a MET Fusion-positive Cholangiocarcinoma
por: Turpin, Anthony, et al.
Publicado: (2023)

Dynamics of circulating tumor DNA represented by the activating and resistant mutations in epidermal growth factor receptor tyrosine kinase inhibitor treatment
por: Uchida, Junji, et al.
Publicado: (2016)

Numerical indices based on circulating tumor DNA for the evaluation of therapeutic response and disease progression in lung cancer patients
por: Kato, Kikuya, et al.
Publicado: (2016)

Protein and mRNA expression of folic acid-associated enzymes as biomarkers for the cytotoxicity of the thymidylate synthase-targeted drugs, pemetrexed and S-1, in non-small cell lung cancer
por: Kimura, Madoka, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_ll0uoto89fn36rg720lcmru5n0